Novel Biomechanical Analysis of Pancreatic Tumours Can Be Used for Both Diagnosis and Prediction of Short-Term Surgical Outcomes


Aidan O'Dowling^{1,2,3}, Micheal Hanly⁴, Dermot O'Toole⁴, Fergal Donnellan⁴, Brian Rodriguez^{2,5}, Niall Swan⁶, Stephen Thorpe^{1,2}, Tom Gallagher^{1,3}

1. School of Medicine, University College Dublin, Belfield, Dublin 4 3. Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4 4. Department of Gastroenterology, St Vincent's University Hospital, Elm Park, Dublin 4 5. School of Physics, University College Dublin, Belfield, Dublin 4

aidanodowling@gmail.com

Background

- Around 600 people are diagnosed with pancreatic cancer in Ireland each year
- Five-year-survival for the most common type, Pancreatic Ductal Adenocarcinoma (PDAC), is around 10%
- Pancreatic cancer is currently the fourth highest cause of cancer-related mortality in Europe¹
- By 2040, pancreatic cancer is predicted to be the second most common cause of cancer-related mortality after lung²
- The most common method for tissue diagnosis is endoscopic ultrasound fine needle biopsy (EUS FNB)
- Post-operative pancreatic fistulae (POPF) are intra-abdominal leaks of pancreatic fluid following pancreatic surgery
- Classified by the International Study Group on Pancreatic Surgery in 2016³
- ~15% of patients develop Grade B or C POPF
- Associated with further morbidity and mortality




1. Joint Research Centre, European Commission; 2. JAMA Network Open (2021); 3. Surgery (2016)

Resection Patients

Pt	Diagnosis	Location	Operation	Stage	POPF	Grade	BMI	Pr
1	Ampullary Adenoca	Ampulla	Whipple	pT1a N0	Y	A	25.9	36
2	PDAC	Tail	Distal	pT3 N2	N	-	29.6	45
3	PDAC	Tail	Distal	pT2 N1	N	-	37.4	49
4	Ampullary Adenoca	Ampulla	Whipple	pT3b N2	N	-	26.9	37
5	Ampullary Adenoca	Ampulla	Whipple	pT3a N1	Y	A	22.1	33
6	IAPN (LGD)	Ampulla	Whipple	N/A	Y	В	35.8	41
7	PDAC	Head	Whipple	ypT2 N0	Ν	-	30.9	37





Tissue	S (
Non-Tumour Adjacent Epithelium (median, IQR)	0) (*
Non-Tumour Adjacent Stroma (median, IQR)	5 (2
Tumour Gland (median, IQR)	9 (;
Tumour Stroma (median, IQR)	1 (!

2. Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4 6. Department of Pathology, St Vincent's University Hospital, Elm Park, Dublin 4









IRISH RESEARCH COUNCIL

St. Vincent's Foundation

Diagnosis	No. of Patients	Sample Modulus (Pa) (median, IQR)
Metastatic PDAC	5	2200 (1030 – 4640)
Non-Metastatic PDAC	1	250 (175 – 375)
Neuroendocrine Tumour	1	2000 (569 – 6410)